Market Overview:
The global emerging cancer diagnostics market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of cancer, technological advancements in diagnostic methods, and rising awareness about early diagnosis and treatment of cancer. The global emerging cancer diagnostics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into men’s cancers and women’s cancers. The men’s cancers segment accounted for the largest share in 2017 owing to high incidence rates for prostate cancer, lung cancer, and blood cancers such as leukemia and lymphoma. However, over time there has been an increase in cases of women’s cancers also due to changing lifestyles (smoking), obesity rates (breastcancer), etc., which is expected to result in a higher growth rate for this segment during the forecast period from 2018-2030.
Product Definition:
Emerging cancer diagnostics is the process of detecting cancers at an earlier, more treatable stage. This can be done through the use of specific biomarkers that are associated with cancer, or through screenings for early signs and symptoms of the disease. The importance of emerging cancer diagnostics is that it can help to improve patient outcomes by providing physicians with earlier information about a patient's condition. This allows for more timely treatment decisions and potentially leads to longer survival rates for those affected by cancer.
Men:
The global men, it's usage and growth factor in emerging cancer diagnostics market size was valued at USD 6.5 billion in 2015 and is expected to grow with CAGR of XX% over the forecast period. Rising prevalence of oncology diseases such as prostate cancer, testicular cancer, lung cancer & breast carcinoma among other malignancies is anticipated to drive the demand for men’s health products including tests & screening tools during the forecast period.
Women:
The global women and it's usage in emerging cancer diagnostics market size was valued at USD 6.5 billion in 2016 and is expected to grow with a CAGR of XX% over the forecast period.
Application Insights:
The blood cancer segment dominated the market in 2017 owing to increasing incidence of blood disorders, such as leukaemia and myeloma. According to the Blood Cancer Foundation, an American non-profit organization dedicated to funding research for blood cancer, around 80% of all funding goes towards research in the U.S., which accounts for over 25% of all diagnosed cases globally each year. This factor is anticipated to fuel growth during the forecast period.
Prostate cancer diagnosis is expected to witness significant growth during the forecast period due largely on advancements in prostate specific antigen (PSA) testing technology and rising awareness among men regarding early detection of prostatecancer symptoms. The other applications include breast and lung cancers screening tests that are currently under investigation or development stages respectively.
Regional Analysis:
North America emerged as the leading regional market in 2017. Key factors contributing to its growth include a rise in government funding for cancer research, technological advancements, and high prevalence of cancer among the U.S. population. For instance, according to data published by the National Cancer Institute (NCI), around 1,762,590 new cases were estimated to be diagnosed in 2019 within the country as well as an additional 967,910 deaths that same year owing to various cancers.
Asia Pacific is expected to register significant growth over the forecast period due to increasing disposable income levels.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related cancers. According to the World Health Organization (WHO), there were 14 million new cases of cancer in 2012, and this number is expected to rise to 21 million by 2030. This presents a huge opportunity for the emerging cancer diagnostics market.
- Advances in technology: Technological advances are helping researchers develop better diagnostic tests for detecting various types of cancers at an early stage. For instance, next-generation sequencing (NGS) technology is being used for developing targeted molecular diagnostics tests that can detect specific genetic mutations associated with different types of cancers. Such technological advances are likely to fuel growth in the emerging cancer diagnostics market over the next few years.
- Growing demand for personalized medicine: There is growing demand for personalized medicine, especially among patients with advanced or metastatic cancers who do not respond well to traditional therapies such as chemotherapy or radiation therapy . Personalized medicine involves using information about a patient’s genes or proteins to select treatments that are most likely to be effective against that particular patient’s tumor . The emergence of novel biomarkers and companion diagnostics has helped fuel this trend, and this is likely to benefit players operating in the emerging cancer diagnostics market over the long term .
Scope Of The Report
Report Attributes
Report Details
Report Title
Emerging Cancer Diagnostics Market Research Report
By Type
Men, Women
By Application
Blood Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Others
By Companies
Abbott Laboratories, Danaher, Agilent Technologies, AstraZeneca, BD, Biocept, Illumina, Luminex, NeoGenomics, QIAGEN, Thermo Fisher Scientific
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Emerging Cancer Diagnostics Market Report Segments:
The global Emerging Cancer Diagnostics market is segmented on the basis of:
Types
Men, Women
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Blood Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Danaher
- Agilent Technologies
- AstraZeneca
- BD
- Biocept
- Illumina
- Luminex
- NeoGenomics
- QIAGEN
- Thermo Fisher Scientific
Highlights of The Emerging Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Men
- Women
- By Application:
- Blood Cancer
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Emerging Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Emerging cancer diagnostics is a term used to describe the latest in cancer detection and treatment technologies. Emerging cancer diagnostics can help doctors diagnose and treat cancers more quickly and accurately, often using less invasive techniques than traditional methods.
Some of the major companies in the emerging cancer diagnostics market are Abbott Laboratories, Danaher, Agilent Technologies, AstraZeneca, BD, Biocept, Illumina, Luminex, NeoGenomics, QIAGEN, Thermo Fisher Scientific.
The emerging cancer diagnostics market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Emerging Cancer Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Emerging Cancer Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Emerging Cancer Diagnostics Market - Supply Chain
4.5. Global Emerging Cancer Diagnostics Market Forecast
4.5.1. Emerging Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Emerging Cancer Diagnostics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Emerging Cancer Diagnostics Market Absolute $ Opportunity
5. Global Emerging Cancer Diagnostics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Emerging Cancer Diagnostics Market Size and Volume Forecast by Type
5.3.1. Men
5.3.2. Women
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Emerging Cancer Diagnostics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Emerging Cancer Diagnostics Market Size and Volume Forecast by Application
6.3.1. Blood Cancer
6.3.2. Prostate Cancer
6.3.3. Breast Cancer
6.3.4. Lung Cancer
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Emerging Cancer Diagnostics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Emerging Cancer Diagnostics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Emerging Cancer Diagnostics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Emerging Cancer Diagnostics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Emerging Cancer Diagnostics Demand Share Forecast, 2019-2029
9. North America Emerging Cancer Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Emerging Cancer Diagnostics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Emerging Cancer Diagnostics Market Size and Volume Forecast by Application
9.4.1. Blood Cancer
9.4.2. Prostate Cancer
9.4.3. Breast Cancer
9.4.4. Lung Cancer
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Emerging Cancer Diagnostics Market Size and Volume Forecast by Type
9.7.1. Men
9.7.2. Women
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Emerging Cancer Diagnostics Demand Share Forecast, 2019-2029
10. Latin America Emerging Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Emerging Cancer Diagnostics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Emerging Cancer Diagnostics Market Size and Volume Forecast by Application
10.4.1. Blood Cancer
10.4.2. Prostate Cancer
10.4.3. Breast Cancer
10.4.4. Lung Cancer
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Emerging Cancer Diagnostics Market Size and Volume Forecast by Type
10.7.1. Men
10.7.2. Women
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Emerging Cancer Diagnostics Demand Share Forecast, 2019-2029
11. Europe Emerging Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Emerging Cancer Diagnostics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Emerging Cancer Diagnostics Market Size and Volume Forecast by Application
11.4.1. Blood Cancer
11.4.2. Prostate Cancer
11.4.3. Breast Cancer
11.4.4. Lung Cancer
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Emerging Cancer Diagnostics Market Size and Volume Forecast by Type
11.7.1. Men
11.7.2. Women
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Emerging Cancer Diagnostics Demand Share, 2019-2029
12. Asia Pacific Emerging Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Emerging Cancer Diagnostics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Emerging Cancer Diagnostics Market Size and Volume Forecast by Application
12.4.1. Blood Cancer
12.4.2. Prostate Cancer
12.4.3. Breast Cancer
12.4.4. Lung Cancer
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Emerging Cancer Diagnostics Market Size and Volume Forecast by Type
12.7.1. Men
12.7.2. Women
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Emerging Cancer Diagnostics Demand Share, 2019-2029
13. Middle East & Africa Emerging Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Emerging Cancer Diagnostics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Emerging Cancer Diagnostics Market Size and Volume Forecast by Application
13.4.1. Blood Cancer
13.4.2. Prostate Cancer
13.4.3. Breast Cancer
13.4.4. Lung Cancer
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Emerging Cancer Diagnostics Market Size and Volume Forecast by Type
13.7.1. Men
13.7.2. Women
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Emerging Cancer Diagnostics Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Emerging Cancer Diagnostics Market: Market Share Analysis
14.2. Emerging Cancer Diagnostics Distributors and Customers
14.3. Emerging Cancer Diagnostics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Danaher
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Agilent Technologies
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. BD
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biocept
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Illumina
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Luminex
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. NeoGenomics
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. QIAGEN
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Thermo Fisher Scientific
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
